Alcon Inc.

ALC • Medical - Specialties

$67.50

▼ -0.33 (-0.49%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL FAVORABLEAtractivaConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil sólido con apoyo razonable de valoración. Los datos sugieren una combinación equilibrada entre calidad y precio.

Capitalización

$33.16B

Crecimiento

4.7%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Crecimiento positivo de ingresos · 5.6%Flujo de caja libre positivo · 3.49Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.24Liquidez saludable · 2.12

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 5 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 12 ago 2026, 12:35 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$67.50

Change-0.49%

Shares Out490.20M

Market Cap$33.16B

Enterprise Value$36.33B

52W Range61.84 - 90.41

Beta0.70

P/E40.67

P/S3.13

P/B1.49

P/FCF20.32

EV/Sales3.43

Price$67.50

Change-0.49%

Shares Out490.20M

Market Cap$33.16B

Enterprise Value$36.33B

52W Range61.84 - 90.41

Beta0.70

P/E40.67

P/S3.13

P/B1.49

P/FCF20.32

EV/Sales3.43

EV/EBITDA17.10

EV/FCF22.26

Earnings Yield2.46%

FCF Yield4.92%

Dividend Yield0.51%

Gross Margin55.24%

Oper. Margin13.08%

Profit Margin9.42%

Debt/Eq0.24

Current Ratio2.12

Quick Ratio1.33

Revenue 5Y4.65%

FCF 5Y7.45%

Target$72.88

Target Upside7.97%

Target Median$76.50

Target Range35.00 - 85.00

Volume3.69M

Avg Volume2.06M

EPS Surprise0.05

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

69/100

Fortaleza financiera

Deuda, caja, estabilidad

74/100

Potencial de crecimiento

Ingresos y expansión

84/100

Atractivo del precio

Barata o cara hoy

61/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 5.6%Flujo de caja libre positivo · 3.49Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.24Liquidez saludable · 2.12Múltiplo de ganancias caro · 39.8

Analyst view

Analyst sentiment and price target

ALC

Analyst sentiment

Based on 26 analyst votes · 2026-10-20

73/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-12

Bajo

$70.00

Promedio

$82.83

Mediana

$83.50

Alto

$97.00

Resumen de la compañía

IPO: 4/9/2019

Industria: Medical - Specialties

P/B i: 1.49

Deuda / Patrimonio i: 0.24

Margen operativo: 13.08%

Margen neto: 9.42%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.24

Ratio corriente: 2.12

Ratio rápido: 1.33

Estado: Good

🧾

No hay actividad interna

No hay transacciones internas recientes disponibles.

Sobre la compañía

Alcon Inc.

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Fuente - Link

Competidores

A BDX CAH GEHC HUM INSM IQV MTD RMD WST

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

GENEVA--(BUSINESS WIRE)--Alcon Acquires Neurotech and ENCELTO, the Only FDA Approved Treatment for MacTel Type 2.

Business Wire

Algoma Central Corporation Announces $62.5 million Offering of 6.20% Convertible Unsecured Subordinated Debentures

CATHARINES, ONTARIO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Algoma Central Corporation (“Algoma”) (TSX:ALC) announced today that it has entered into an agreement to sell, on a bought deal basis to a syndicate of underwriters led by CIBC Capital Markets, $50,000,000 aggregate principal amount of 6.20% convertible unsecured subordinated debentures (the “Debentures”) at a price of $1,000 per Debenture (the “Public Offering”).

GlobeNewsWire

FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.

Business Wire

FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.

Business Wire

Credo Expands AI Connectivity Portfolio With 1.6T ZeroFlap ALC

CRDO expands its AI connectivity portfolio with the 1.6T ZeroFlap Active Light Cable, offering lower power consumption, enhanced reliability and extended reach.

Zacks Investment Research

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-05	0.8	0.85	0.05
2026-02-24	0.79	0.78	-0.01
2025-11-11	0.77	0.79	0.02
2025-08-19	0.71	0.76	0.05
2025-05-13	0.76	0.73	-0.03
2025-02-25	0.7	0.72	0.02
2024-11-12	0.72	0.81	0.09
2024-08-20	0.74	0.74	0
2024-05-13	0.72	0.78	0.06
2024-02-27	0.68	0.69	0.01
2023-11-14	0.67	0.66	-0.01
2023-08-15	0.62	0.69	0.07